H.C. Wainwright lowered the firm’s price target on Esperion Therapeutics to $16 from $22 and keeps a Buy rating on the shares post the Q4 report. The analyst believes the company’s revenue should see an important inflection point starting in the second half of 2024 following the expected label expansion based on the positive survival data from the CLEAR Outcome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ESPR:
- Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
- Esperion sees 2024 operating expenses $225M-$245M
- Esperion reports Q4 EPS (50c), consensus (48c)
- ESPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
